Eli Lilly & Co. (LLY) volatility elevated into Alzheimer's data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM ESTLeerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.
Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM ESTBMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).
Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More
Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM ESTLeerink Partners analyst Seamus Fernandez weighed in on Eli Lilly & Co. (NYSE: LLY) after sola failed, saying this makes the future of the company's AD portfolio uncertain.
Fernandez commeted, "This morning LLY announced that its EXPEDITION 3 trial of solanezumab (sola) did NOT... More
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM ESTEli Lilly & Co. (NYSE: LLY) CEO John Lechleite says there's no concern about the company's dividend, according to CNBC.
David A. Ricks. Senior Vice President and President, Lilly Bio-Medicines, also added that investors want the company to continue exploring solutions for Alzheimer's disease.
... MoreEli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM ESTEli Lilly & Co. (NYSE: LLY) falls 11% after the company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... More